Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol dose comparison with reduced-dose thiopurines in inflammatory bowel disease shunters
ACTRN12611000363987Phase 4Completed
- Sponsor
- The Alfred Hospital
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of allopurinol in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by The Alfred Hospital. Primary endpoint: Steroid-free remission at 24 weeks. Started Apr 2011; status: completed.
02
Drugs
allopurinol
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on ACTRN12611000363987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000363987.